Eleventh Circuit Upholds False Claims Act Whistleblower Provisions in Florida Medicare Case

The U.S. Court of Appeals for the Eleventh Circuit ruled on September 1 that the whistleblower provisions of the False Claims Act are constitutional, reversing a decision from the Middle District of Florida that had struck them down and reviving a Medicare Advantage fraud case brought by a Florida physician. The ruling has immediate consequences for health care fraud enforcement across Florida, Georgia and Alabama, the three states within the circuit's jurisdiction.

The court held that private parties who sue under the False Claims Act, known in the statute as relators, are not "Officers of the United States," and that the law's qui tam provisions therefore do not violate the Appointments Clause of the Constitution. That conclusion vacated a 2024 ruling by U.S. District Judge Kathryn Kimball Mizelle, who had reached the opposite result and dismissed the underlying case.

The case now returns to the district court, where the Eleventh Circuit directed the judge to consider two additional constitutional theories that the earlier ruling had not reached. The whistleblower's substantive allegations against her former employer remain unresolved and untested.

What the case is about

The lawsuit was filed by Dr. Clarissa Zafirov, a board-certified family care physician, against Florida Medical Associates LLC and related entities doing business as VIPcare. Zafirov alleged that her former employer systematically submitted false diagnosis codes in the Medicare Advantage program in order to inflate the monthly risk-adjustment payments the organization received.

Medicare Advantage operates differently from traditional Medicare. Rather than paying providers for each service rendered, the federal government pays private plans a fixed monthly amount per enrollee, adjusted upward for patients whose documented diagnoses indicate greater expected medical need. That structure creates a financial incentive to document conditions thoroughly, and it creates a corresponding opportunity for abuse when diagnoses are recorded that the patient does not have.

Risk-adjustment fraud has become one of the most heavily litigated areas of federal health care enforcement over the past decade. The Department of Justice has pursued cases against plans and provider groups nationwide, and the theory advanced in Zafirov's complaint follows a pattern that has appeared in numerous other actions. The allegations remain allegations, and no finding has been made on their merits.

How qui tam actions work

The False Claims Act dates to the Civil War and was enacted to address fraud against the federal government by military contractors. Its distinguishing feature is a provision allowing private citizens with knowledge of fraud to file suit on the government's behalf, a mechanism inherited from English law and known as qui tam.

A relator files the complaint under seal, and the Department of Justice then investigates and decides whether to intervene and take over the litigation. If the government declines, the relator may proceed alone. Successful actions return recovered funds to the Treasury, with the relator receiving a percentage that varies depending on whether the government intervened and on the relator's contribution to the outcome.

The statute has become the federal government's principal civil tool against fraud in health care, defense contracting and other areas of federal spending. The Department of Justice has reported recoveries in the billions of dollars annually in recent years, with health care matters accounting for the majority. A substantial share of those cases originate with private whistleblowers rather than with government investigators.

The constitutional challenge

The Appointments Clause of the Constitution specifies how officers of the United States must be selected, requiring presidential nomination and Senate confirmation for principal officers and permitting Congress to vest appointment of inferior officers in the President, the courts or department heads. The argument advanced against the qui tam provisions was that a relator prosecuting a case on the government's behalf exercises executive power and must therefore be appointed in one of those ways.

Judge Mizelle accepted that argument in 2024, concluding that the whistleblower provision improperly allows private citizens to wield executive branch authority without any of the constitutional mechanisms that ordinarily accompany such authority. The ruling was the first of its kind from a federal district court and drew substantial attention from the defense bar and from organizations representing whistleblowers.

The Eleventh Circuit disagreed. Its holding that relators are not officers of the United States rests on the distinction between exercising continuing governmental authority and pursuing a private civil action in which the government retains ultimate control, including the ability to intervene, to settle and in certain circumstances to dismiss the case entirely.

What the ruling does and does not resolve

The decision resolves the Appointments Clause question within the Eleventh Circuit but leaves other constitutional theories open. The appeals court specifically directed the district court to address two arguments it had not previously reached, which means the defendants retain avenues to challenge the statute on remand.

The ruling also does not address the merits of Zafirov's allegations. Whether VIPcare submitted false diagnosis codes, whether any such submissions were knowing within the meaning of the statute, and what damages if any resulted are all questions that remain for the district court and, potentially, a jury.

Because the decision creates binding precedent only within the Eleventh Circuit, similar challenges may proceed in other circuits. A division among the courts of appeals on a question of this significance would substantially increase the likelihood of Supreme Court review, and observers of federal fraud litigation have identified the issue as one that could reach the high court.

Why this matters for Florida

Florida has one of the largest Medicare populations in the country, a consequence of demographics that have made the state a destination for retirees for generations. Medicare Advantage enrollment in Florida is correspondingly large, and the state has among the highest penetration rates for those plans nationally.

That concentration makes Florida a focal point for both the program's operation and its enforcement. The U.S. Attorney's Offices for the Middle and Southern Districts of Florida have pursued numerous health care fraud matters, and the state's density of provider organizations, plans and specialty practices produces a steady volume of qui tam filings.

For Florida patients, the practical stake in risk-adjustment enforcement is somewhat indirect but real. Payments made on the basis of inaccurate diagnoses come from the Medicare trust funds, which are financed through payroll taxes and premiums. Inaccurate diagnosis records can also follow a patient through subsequent care, complicating treatment decisions made by providers relying on the documented history.

The health care industry response

The district court ruling that the Eleventh Circuit has now reversed had been received with considerable interest by health care organizations facing qui tam exposure. Had it been upheld and extended, it would have eliminated the principal mechanism through which fraud allegations in the industry reach federal court.

Industry groups have long argued that the False Claims Act as applied to health care produces litigation over billing disputes and documentation disagreements that are more properly resolved administratively, and that the statute's damages provisions, which include treble damages and per-claim penalties, create settlement pressure disproportionate to the underlying conduct.

Whistleblower advocates counter that the statute is the primary reason fraud in federally funded programs is detected at all, since the individuals with direct knowledge are employees rather than regulators, and that the financial incentive is what overcomes the substantial career risk of reporting. Both arguments have been made in Congress repeatedly, and the statute has been amended several times in response.

Whistleblower protections in practice

The False Claims Act includes anti-retaliation provisions that allow an employee who suffers adverse action for pursuing or supporting a qui tam claim to seek reinstatement, back pay and other relief. Those protections exist because the practical reality for most relators involves the end of their employment and, frequently, difficulty finding comparable work in the same field.

Cases typically take years to resolve. Complaints remain under seal while the government investigates, a period that statute sets at 60 days but that courts routinely extend, sometimes for years. During that time the relator generally cannot discuss the case, including with prospective employers seeking to understand a gap in employment.

Attorneys who practice in the area generally advise potential relators that the process is lengthy, that most cases produce no recovery, and that the decision to file carries professional consequences that should be weighed carefully. Those realities shape who ultimately brings these cases and why the financial incentive exists in the statute.

Enforcement trends in Medicare Advantage

Federal scrutiny of risk-adjustment practices has intensified substantially over the past several years. The Department of Health and Human Services Office of Inspector General has published a series of reports examining diagnosis codes that generated payments without corresponding evidence of treatment, and audits of individual plans have identified payment discrepancies.

The Centers for Medicare and Medicaid Services has also revised its audit methodology for Medicare Advantage plans, including changes to how audit findings are extrapolated across a plan's enrollment. Those methodological questions carry enormous financial consequences, since extrapolation converts findings from a sample into liability across an entire population.

Litigation over those audit rules has proceeded alongside the fraud cases themselves, and the two tracks interact. Provider organizations and plans have argued that enforcement is being applied to documentation practices that regulators previously accepted, while the government has maintained that the standard has been consistent.

The road back to district court

With the Appointments Clause question resolved within the circuit, the case returns to the Middle District of Florida for consideration of the remaining constitutional arguments. Those proceedings will address theories the earlier ruling did not need to reach, and the outcome will determine whether the case proceeds toward discovery on the merits.

If the statute survives those challenges, the litigation would move into the substantive phase, where the questions become factual rather than constitutional. Discovery in risk-adjustment cases typically involves extensive review of medical records, coding practices and internal communications, and the process routinely extends across multiple years.

Defendants retain the option of seeking further appellate review, including a petition for rehearing before the full Eleventh Circuit or a petition to the Supreme Court. Neither step is automatic, and both are granted infrequently, but the constitutional significance of the question makes this case a more plausible candidate than most.

What's next

The immediate procedural step is the return of the case to the district court and briefing on the theories the Eleventh Circuit identified. That process will unfold over the coming months and will determine whether the constitutional challenge is finally resolved or continues.

Beyond this case, the ruling stabilizes False Claims Act practice within the Eleventh Circuit, which had been operating under uncertainty since the 2024 district court decision. Qui tam filings in Florida and the other states in the circuit can proceed without the threat that the statutory basis for the action will be invalidated.

The Florida Press will follow the case through the district court proceedings and will report on further appellate developments, including any petition for Supreme Court review.